Medicare Part B cancer drugs sales price per dosage U.S. 2014

This statistic displays the leading Medicare Part B cancer drugs based on average sales price per dosage in 2014, in U.S. dollars. The average sales price for one dose (1 mg) of a Denosumab injection totaled 14.45 U.S. dollars. The size and demographic of medical professionals in oncology plays a significant role in the accessibility and quality of cancer care for patients in the United States.

Leading Medicare Part B cancer drugs based on average sales price per dosage in 2014 (in U.S. dollars)

Name (dose)	Sales price per dosage in U.S. dollars
Pegfilgrastim injection* (6mg)	3,387.93
Aflibercept injection* (0.1mg)	980.5
Rituximab injection* (100mg)	708.68
Ranibizumab injection (0.1mg)	396.43
Trastuzumab injection* (10mg)	82.49
Infliximab injection (10mg)	74.34
Bevacizumab injection* (10mg)	66.65
Pemetrexed injection* (10mg)	60.27
Bortezomib injection* (0.1mg)	46.08
Denosumab injection* (1mg)	14.45

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Source

Use Ask Statista Research Service

Release date

March 2016

More information

Region

United States

Survey time period

2014

Supplementary notes

Values are for drugs delivered in the physician office and at home.
* Drugs used for treatment of patients with cancer. Pricing data reflects 4th quarter 2014 payment rates, which correspond to 2nd quarter 2014 manufacturer reports.

Citation formats